Fig. 1
Treatment with HDACis prior to PMX mediates reduced PMX sensitivity. (A) Treatment schedule; A549 cells were pre-treated with 5 µM MS275 for 12 h prior to treatment with various concentrations of PMX for 48 h, as indicated in Fig. 1B (0.5 µM PMX was used in C and D). (B) Resazurin cell viability assays demonstrated that MS275 pretreatment mediated reduced sensitivity towards PMX. Each data point represents an average of three parallel wells relative to untreated wells with standard deviation indicated. (C) Flow cytometry analysis of cell cycle distribution after the various treatments at. (D) Western analysis of A549 whole cell extracts after the various treatments, including treatment with SAHA (60 h) that mediates less robust UNG2 depletion than MS275. Full western blots related to Fig. 1D are provided in Supplementary Figure S2.
